Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)‘s stock had its “outperform” rating reissued by research analysts at Oppenheimer Holdings, Inc. in a research note issued on Tuesday. They presently have a $9.00 target price on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price target would suggest a potential upside of 106.90% from the company’s current price.

A number of other brokerages also recently issued reports on SGYP. BTIG Research reissued a “buy” rating and set a $11.00 price target on shares of Synergy Pharmaceuticals in a research report on Saturday, April 22nd. Zacks Investment Research downgraded Synergy Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Canaccord Genuity reissued a “buy” rating and set a $13.00 price target on shares of Synergy Pharmaceuticals in a research report on Monday, July 10th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Synergy Pharmaceuticals in a research report on Monday, June 12th. Finally, ValuEngine downgraded Synergy Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 23rd. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Synergy Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $10.67.

Synergy Pharmaceuticals (SGYP) traded down 2.7977% during trading on Tuesday, hitting $4.2283. The company had a trading volume of 1,325,409 shares. The stock has a 50-day moving average of $4.05 and a 200 day moving average of $4.99. Synergy Pharmaceuticals has a one year low of $3.34 and a one year high of $7.15. The company’s market capitalization is $951.15 million.

Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.07. The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million. Equities analysts forecast that Synergy Pharmaceuticals will post ($0.95) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/07/18/oppenheimer-holdings-inc-reaffirms-outperform-rating-for-synergy-pharmaceuticals-inc-nasdaqsgyp.html.

A number of large investors have recently added to or reduced their stakes in the company. Tudor Investment Corp Et Al boosted its stake in Synergy Pharmaceuticals by 1.3% in the fourth quarter. Tudor Investment Corp Et Al now owns 18,376 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 232 shares during the last quarter. Amalgamated Bank boosted its stake in Synergy Pharmaceuticals by 7.9% in the first quarter. Amalgamated Bank now owns 24,013 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,758 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in Synergy Pharmaceuticals by 27.4% in the first quarter. Janney Montgomery Scott LLC now owns 30,200 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 6,500 shares during the last quarter. Stifel Financial Corp boosted its stake in Synergy Pharmaceuticals by 34.4% in the first quarter. Stifel Financial Corp now owns 30,289 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 7,750 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in Synergy Pharmaceuticals by 12.9% in the first quarter. Principal Financial Group Inc. now owns 37,343 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 4,267 shares during the last quarter. Hedge funds and other institutional investors own 67.37% of the company’s stock.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Analyst Recommendations for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.